Background
The mechanism(s) by which arsenic produces bladder cancer are unknown. Additionally, the toxic effects of low-level arsenic exposure to produce bladder injury have not been adequately examined.
Goal
To clarify the toxic effects of low-level arsenic in a human bladder model and provide potential biomarkers for arsenic-induced bladder injury.
Image shows enhanced accumulation of ubiquinated proteins in UROtsa cells treated with BSO and exposed to As(III). B = BSO treated.
Objectives 1. Determine the role of biotransformation of arsenic in the bladder to produce sub-cytotoxic effects.
2. Determine if low-level arsenic exposure to the bladder is producing toxicity via proteotoxic mechanisms.
3. Determine if low-level arsenic exposure to the bladder produces toxicity via an oxidative stress mechanism.
4. Determine if low-level arsenic exposure to the bladder is affecting the ubiquitin pathway and its toxic consequences.
5. Using the above information, determine if biomarkers of arsenic-induced bladder injury are present in human bladder samples. Contact A. Jay Gandolfi gandolfi@pharmacy.arizona.edu
(520) 626-6696
Molecular Effects of Low Level Arsenic on the Human Bladder
Superfund Basic Research Program
The University of Arizona
College of Pharmacy, Room 331
Tucson, Arizona 85721-0207
P: 520-626-7101
F: 520-626-2466